Sylvia Hartl

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

Medicine, Oncology, Pharmacology +14

Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial

Thomas Köhnlein, Wolfram Windisch, Dieter Köhler et al. · The Lancet Respiratory Medicine · 2014 · 806 citations

Medicine, Clinical Sciences, Internal Medicine +11

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 687 citations · Full text

Medicine, Oncology, Pharmacology +14

Differences in content and organisational aspects of pulmonary rehabilitation programmes

Martijn A. Spruit, Fábio Pitta, Chris Garvey et al. · European Respiratory Journal · 2013 · 298 citations · Full text

Health Professions, Clinical Sciences, Rehabilitation Medicine +12

Incidence and outcome of weaning from mechanical ventilation according to new categories

G-C. Funk, Shilo Anders, M.-K. Breyer et al. · European Respiratory Journal · 2009 · 277 citations · Full text

Health Professions, Surgery, Pulmonology +16